|Bid||2.23 x 1100|
|Ask||2.25 x 800|
|Day's Range||2.22 - 2.36|
|52 Week Range||2.22 - 5.70|
|Beta (3Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
MORRISVILLE, N.C., Nov. 20, 2018 -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Paula Brown Stafford, Chief Development Officer, and Nathan.
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)Adding reSET to outpatient therapy significantly improved abstinence.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced positive preliminary top line results for three full cohorts of four from the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum. SB206 gel demonstrated a clear treatment effect on the complete clearance of all molluscum lesions at Week 12, with signs of efficacy evident as early as Week 4 for the two highest doses, 8% and 12% twice-daily.
Novan (NOVN) delivered earnings and revenue surprises of 15.63% and -4.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that the Company will host a conference call on Wednesday, November 14, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress.
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that data from the Company’s Phase 2 clinical trial evaluating SB206, a topical nitric oxide-releasing product candidate for the treatment of external genital warts caused by human papillomavirus (HPV), have been published in the October 2018 issue of Journal of Drugs in Dermatology, a peer-reviewed journal in dermatology with high readership and exposure to approximately 14,500 dermatology healthcare professionals. “The data generated in our Phase 2 trial with SB206 for the treatment of external genital warts are encouraging and support the potential for a nitric oxide-based therapy to treat a skin disorder with few treatment options, and possibly other HPV-associated diseases with significant unmet need,” stated Tomoko Maeda-Chubachi, Novan’s Vice President, Medical Dermatology.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has established a strategic alliance with Orion Corporation (“Orion”), a Finnish full-scale pharmaceutical company with broad experience in manufacturing. The alliance enables Orion to manufacture Novan’s topical nitric oxide-releasing product candidates on behalf of Novan and Novan’s global strategic partners.
A Morrisville pharmaceutical company has scored an $11 million agreement with a Japanese company for exclusive rights to sell their skin care medicine.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has expanded its partnership with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a prescription pharmaceutical business specializing in dermatology, to include Novan’s topical nitric oxide-releasing product candidate SB206 for the treatment of viral skin infections including warts and molluscum contagiosum.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that enrollment in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum has fully enrolled all cohorts. Cohorts 3 and 4, SB206 12% twice-daily (BID) and 12% once-daily (QD) respectively, were recruited meaningfully ahead of schedule with enrollment completed in August.
If you own shares in Novan Inc (NASDAQ:NOVN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced receipt of written meeting minutes from a Type C meeting held with the U.S. Food and Drug Administration (FDA) in the second quarter of 2018. As previously communicated, receipt of the meeting minutes is a necessary and critical step in the Company’s assessment and consideration around the advancement of SB204 in acne vulgaris for the U.S. market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 20) Avanos Medical Inc (NYSE: AVNS ) Becton Dickinson and Co (NYSE: ...
Novan Inc (NASDAQ: NOVN) shares were advancing strongly Monday after the announcement of positive results for its pipeline candidate SB414. Novan said its SB414 — a nitric oxide-releasing cream product candidate which is being evaluated for atopic dermatitis and psoriasis — produced positive results in two complementary Phase 1b clinical trials. Clinical efficacy measures based on the trials were found to be highly correlated with critical and disease-relevant biomarker changes, the company said.
Assessing Novan Inc’s (NASDAQ:NOVN) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...